Just when investors thought things couldn't get any worse, they do.
ApexOnco Front Page
Recent articles
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
But the timeline for a US green light is less clear, and the group has a cash crisis.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
